ibrexafungerp
ibrexafungerp: sourced relationships with 1 company · 2 clinical trials tracked.
ibrexafungerp evidence translation
What we can confirm
2 tracked trials
What it means
What to watch
Prepared research question
How could ibrexafungerp → SCYX affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| SCYNEXIS INC (SCYX) Vulvovaginal Candidiasis | Phase 3 |
Clinical Trial Registry Records (2)
Phase 1, Open-Label Pharmacokinetic Study in Healthy Lactating Women After Two Oral Doses of Ibrexafungerp Administered on a Single Day
Primary endpoint: SCY-078 Breast Milk Concentrations.
A Phase 3, Multicenter, Prospective, Randomized, Double-blind Study of Two Treatment Regimens for Candidemia and/or Invasive Candidiasis: Intravenous Echinocandin Followed by Oral Ibrexafungerp Versus Intravenous Echinocandin Followed by Oral Fluconazole (MARIO)
Primary endpoint: All-cause Mortality
Frequently asked questions
Which companies have sourced relationships with ibrexafungerp?
ibrexafungerp has dated SEC/FDA relationship records for SCYNEXIS INC.
How many clinical trials involve ibrexafungerp?
BioSniper tracks 2 clinical trials involving ibrexafungerp.